Deriving high-quality evidence from national healthcare databases to improve suicidality detection and treatment outcomes in PTSD

从国家医疗保健数据库中获取高质量证据,以改善 PTSD 的自杀检测和治疗结果

基本信息

项目摘要

PROJECT SUMMARY Post-traumatic stress disorder (PTSD) often has complex profiles of co-occurring medical conditions and is associated with high risk of self-harm, including suicidality, which is a leading cause of death, particularly among Veterans. There is a critical lack of advancement in PTSD pharmacotherapy, as illustrated by increased use of off-label medications and polypharmacy (multiple drugs used simultaneously) with limited evidence on their relative risks and benefits. Moreover, PTSD and suicidal and nonsuicidal self-harm often remain undocumented in electronic health records (EHR). There is also poor predictability of disease outcomes since there are frequent changes in pharmacological treatment and multiple modifying co-occurring conditions including depression, bipolar disorder, schizophrenia, substance use disorders, traumatic brain injury, and sleep disorders. Our long-term goal is to improve diagnostics, secondary/tertiary prevention, and treatment outcomes of PTSD and its co-occurring conditions via enhanced EHR utilization. To achieve our objectives, we will analyze EHR and administrative claims data from Veterans Health Administration (VHA) and non-VHA databases, collectively covering >1.8M patients with PTSD. Specifically, we aim to: (1) Identify undetected and uncoded co-occurring mental health phenotypes that impact PTSD outcomes using machine learning and characterize disparities in their documentation; (2) Create robust models, accounting for biases and co-occurring conditions, to identify clinical trajectories of PTSD decompensation/recovery in response to time-varying treatments; and (3) Compare risk of self-harm and hospitalization among PTSD treatments using coded and imputed phenotypes through an international network study. We will compare the effectiveness of PTSD psychotropic monotherapies, polypharmacy, and psychotherapy to guide the choice of treatment for improved patient outcomes. By enhancing and validating a positive-unlabeled machine learning approach developed by our team, we will impute unrecorded/undetected mental health conditions co-occurring with PTSD in both VHA and non-VHA databases, and characterize factors associated with documentation disparities. We will model disease trajectories with enhanced latent class / latent trajectory analysis, focusing on self-harm, substance use disorders, and psychiatric hospitalization in PTSD. Finally, we will perform the largest comparative effectiveness studies to date of PTSD treatments on >100 monotherapy and polypharmacy regimens, in addition to psychotherapy interventions, using causal models and methods for addressing biases. These studies will provide high-quality evidence on the risk of hospitalizations and suicidal acts/self-harm. Successful completion of these investigations will improve the quality of clinical psychiatric decision-making, and guide improved service delivery to the Veteran and non-Veteran populations with PTSD/TBI, and/or high risk of self-harm/suicidality.
项目总结

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Christophe G. Lambert其他文献

Christophe G. Lambert的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Christophe G. Lambert', 18)}}的其他基金

Deriving high-quality evidence from national healthcare databases to improve suicidality detection and treatment outcomes in PTSD and TBI
从国家医疗保健数据库中获取高质量证据,以改善 PTSD 和 TBI 的自杀检测和治疗结果
  • 批准号:
    10088135
  • 财政年份:
    2020
  • 资助金额:
    $ 74.43万
  • 项目类别:
Illuminating the Druggable Genome Data Coordinating Center - Engagement Plan with the CFDE
阐明可药物基因组数据协调中心 - 与 CFDE 的合作计划
  • 批准号:
    10217890
  • 财政年份:
    2020
  • 资助金额:
    $ 74.43万
  • 项目类别:
Illuminating the Druggable Genome Data Coordinating Center - Engagement Plan with the CFDE
阐明可药物基因组数据协调中心 - 与 CFDE 的合作计划
  • 批准号:
    10683510
  • 财政年份:
    2020
  • 资助金额:
    $ 74.43万
  • 项目类别:
Illuminating the Druggable Genome Data Coordinating Center - Engagement Plan with the CFDE
阐明可药物基因组数据协调中心 - 与 CFDE 的合作计划
  • 批准号:
    10907966
  • 财政年份:
    2020
  • 资助金额:
    $ 74.43万
  • 项目类别:
Illuminating the Druggable Genome Data Coordinating Center - Engagement Plan with the CFDE
阐明可药物基因组数据协调中心 - 与 CFDE 的合作计划
  • 批准号:
    10468527
  • 财政年份:
    2020
  • 资助金额:
    $ 74.43万
  • 项目类别:
A microaggregation framework for reproducible research with observational data: addressing biases while protecting personal identities
利用观察数据进行可重复研究的微聚合框架:在保护个人身份的同时解决偏见
  • 批准号:
    9306948
  • 财政年份:
    2016
  • 资助金额:
    $ 74.43万
  • 项目类别:
Software Relating Genes to Disease and Clinical Outcomes
将基因与疾病和临床结果相关的软件
  • 批准号:
    6341382
  • 财政年份:
    2001
  • 资助金额:
    $ 74.43万
  • 项目类别:
Software Relating Genes to Disease and Clinical Outcomes
将基因与疾病和临床结果相关的软件
  • 批准号:
    6582179
  • 财政年份:
    2001
  • 资助金额:
    $ 74.43万
  • 项目类别:
Software Relating Genes to Disease and Clinical Outcomes
将基因与疾病和临床结果相关的软件
  • 批准号:
    7013551
  • 财政年份:
    2001
  • 资助金额:
    $ 74.43万
  • 项目类别:
Software Relating Genes to Disease and Clinical Outcomes
将基因与疾病和临床结果相关的软件
  • 批准号:
    6693828
  • 财政年份:
    2001
  • 资助金额:
    $ 74.43万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Fellowship
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Continuing Grant
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Research Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 74.43万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了